299 related articles for article (PubMed ID: 7551366)
1. Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment.
Yates DH; Sussman HS; Shaw MJ; Barnes PJ; Chung KF
Am J Respir Crit Care Med; 1995 Oct; 152(4 Pt 1):1170-4. PubMed ID: 7551366
[TBL] [Abstract][Full Text] [Related]
2. Rebound airway obstruction and responsiveness after cessation of terbutaline: effects of budesonide.
de Jong JW; van der Mark TW; Koëter GH; Postma DS
Am J Respir Crit Care Med; 1996 Jan; 153(1):70-5. PubMed ID: 8542165
[TBL] [Abstract][Full Text] [Related]
3. Effect of regular salmeterol treatment on albuterol-induced bronchoprotection in mild asthma.
Yates DH; Worsdell M; Barnes PJ
Am J Respir Crit Care Med; 1997 Sep; 156(3 Pt 1):988-91. PubMed ID: 9310023
[TBL] [Abstract][Full Text] [Related]
4. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
van der Woude HJ; Winter TH; Aalbers R
Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351
[TBL] [Abstract][Full Text] [Related]
5. Is the increase in bronchial responsiveness or FEV1 shortly after cessation of beta2-agonists reflecting a real deterioration of the disease in allergic asthmatic patients? A comparison between short-acting and long-acting beta2-agonists.
van Schayck CP; Cloosterman SG; Bijl-Hofland ID; van den Hoogen H; Folgering HT; van Weel C
Respir Med; 2002 Mar; 96(3):155-62. PubMed ID: 11908511
[TBL] [Abstract][Full Text] [Related]
6. Beta2-adrenoceptor polymorphism and bronchoprotective sensitivity with regular short- and long-acting beta2-agonist therapy.
Lipworth BJ; Hall IP; Aziz I; Tan KS; Wheatley A
Clin Sci (Lond); 1999 Mar; 96(3):253-9. PubMed ID: 10029561
[TBL] [Abstract][Full Text] [Related]
7. Prolonged protection against methacholine-induced bronchoconstriction by the inhaled beta 2-agonist formoterol.
Ramsdale EH; Otis J; Kline PA; Gontovnick LS; Hargreave FE; O'Byrne PM
Am Rev Respir Dis; 1991 May; 143(5 Pt 1):998-1001. PubMed ID: 1673830
[TBL] [Abstract][Full Text] [Related]
8. Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma.
Aziz I; Hall IP; McFarlane LC; Lipworth BJ
J Allergy Clin Immunol; 1998 Mar; 101(3):337-41. PubMed ID: 9525449
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma.
Cheung D; Timmers MC; Zwinderman AH; Bel EH; Dijkman JH; Sterk PJ
N Engl J Med; 1992 Oct; 327(17):1198-203. PubMed ID: 1357550
[TBL] [Abstract][Full Text] [Related]
10. A bolus of inhaled budesonide rapidly reverses airway subsensitivity and beta2-adrenoceptor down-regulation after regular inhaled formoterol.
Aziz I; Lipworth BJ
Chest; 1999 Mar; 115(3):623-8. PubMed ID: 10084466
[TBL] [Abstract][Full Text] [Related]
11. Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial.
Haney S; Hancox RJ
Respir Res; 2005 Sep; 6(1):107. PubMed ID: 16168062
[TBL] [Abstract][Full Text] [Related]
12. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol.
Kalra S; Swystun VA; Bhagat R; Cockcroft DW
Chest; 1996 Apr; 109(4):953-6. PubMed ID: 8635376
[TBL] [Abstract][Full Text] [Related]
13. Rapid onset of tolerance to beta-agonist bronchodilation.
Haney S; Hancox RJ
Respir Med; 2005 May; 99(5):566-71. PubMed ID: 15823453
[TBL] [Abstract][Full Text] [Related]
14. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group.
FitzGerald JM; Chapman KR; Della Cioppa G; Stubbing D; Fairbarn MS; Till MD; Brambilla R
J Allergy Clin Immunol; 1999 Mar; 103(3 Pt 1):427-35. PubMed ID: 10069876
[TBL] [Abstract][Full Text] [Related]
15. Long-term circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids.
Meijer GG; Postma DS; Mulder PG; van Aalderen WM
Am J Respir Crit Care Med; 1995 Dec; 152(6 Pt 1):1887-92. PubMed ID: 8520751
[TBL] [Abstract][Full Text] [Related]
16. An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist.
Yates DH; Kharitonov SA; Barnes PJ
Am J Respir Crit Care Med; 1996 Dec; 154(6 Pt 1):1603-7. PubMed ID: 8970342
[TBL] [Abstract][Full Text] [Related]
17. Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype.
Lipworth BJ; Dempsey OJ; Aziz I; Wilson AM
Am J Med; 2000 Aug; 109(2):114-21. PubMed ID: 10967152
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of formoterol and salbutamol on bronchial hyperreactivity and beta-adrenoceptor density on lymphocytes in children with bronchial asthma.
Kozlik-Feldmann R; von Berg A; Berdel D; Reinhardt D
Eur J Med Res; 1996 Jul; 1(10):465-70. PubMed ID: 9438143
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients.
Palmqvist M; Ibsen T; Mellén A; Lötvall J
Am J Respir Crit Care Med; 1999 Jul; 160(1):244-9. PubMed ID: 10390407
[TBL] [Abstract][Full Text] [Related]
20. Formoterol, a new long-acting selective beta 2-adrenergic receptor agonist: double-blind comparison with salbutamol and placebo in children with asthma.
Becker AB; Simons FE
J Allergy Clin Immunol; 1989 Dec; 84(6 Pt 1):891-5. PubMed ID: 2574732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
